Literature DB >> 12780647

Radiation damage to the rectum and anus: pathophysiology, clinical features and surgical implications.

E. D. Reis1, A. J. Vine, T. Heimann.   

Abstract

Radiation kills cancer cells by inducing various degrees of deoxyribonucleic acid fragmentation and disruption of intracellular membranes that lead to either immediate or delayed cell death. Although radiation can be effective in destroying cancer, its usefulness is limited by damage to normal tissues that surround the target tumour or those in the path of the radiation beam. The rectum and anus are damaged frequently during radiotherapy for abdominopelvic malignancy, including preresection therapy for rectal cancer. Such damage is often associated with lesions in the perineal skin, genitourinary tract, colon, and small intestine. Surgical intervention often is required for the most severe forms of these complications.

Entities:  

Year:  2002        PMID: 12780647     DOI: 10.1046/j.1463-1318.2002.00282.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  4 in total

1.  Radiotherapy for rectal carcinoma: an unusual cause of foreskin phimosis.

Authors:  Jonathan M Featherstone; Andrew Aldridge; A Mark Gudgeon
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  Effect of neoadjuvant chemoradiation on postoperative fecal continence and anal sphincter function in rectal cancer patients.

Authors:  Alexander P Pietsch; Rainer Fietkau; Günther Klautke; Thomas Foitzik; Ernst Klar
Journal:  Int J Colorectal Dis       Date:  2007-05-12       Impact factor: 2.571

3.  Antioxidant Supplementation: A Linchpin in Radiation-Induced Enteritis.

Authors:  Mumtaz Anwar; Shabeer Ahmad; Reyhan Akhtar; Akhtar Mahmood; Safrun Mahmood
Journal:  Technol Cancer Res Treat       Date:  2017-05-22

Review 4.  The role of colonic motility in low anterior resection syndrome.

Authors:  Chris Varghese; Cameron I Wells; Ian P Bissett; Gregory O'Grady; Celia Keane
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.